Status:
RECRUITING
Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
Lead Sponsor:
Instituto Sistemas Complejos de Ingeniería
Conditions:
RSV
Eligibility:
All Genders
Up to 4 years
Brief Summary
The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The pri...
Detailed Description
The primary aim of NirseCL is to evaluate the effectiveness of nirsevimab against Respiratory Syncytial Virus (RSV) in infants during the 2024 RSV season in Chile. The secondary objective is to determ...
Eligibility Criteria
Inclusion
- Subjects born between October 1st, 2023, to September 31st, 2024.
- Subjects born with 29 weeks of gestational age (wga) or less who were born between July 1st, 2023 and October 1st, 2023
- Subjects born with Bronchopulmonary Dysplasia (BPD), 32 or less wga and/or a birth weight less than 1·5 kgs born between April 1st, 2023 and October 1st, 2023.
Exclusion
- No specific criteria has been reported
Key Trial Info
Start Date :
April 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
160000 Patients enrolled
Trial Details
Trial ID
NCT06511687
Start Date
April 1 2024
End Date
October 1 2024
Last Update
July 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ISCI
Santiago, Chile, 8370398